PA
IDXX icon

Pinnacle Associates’s Idexx Laboratories IDXX Stock Holding History

Pinnacle Associates’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$573K Sell
1,089
-137
-11% -$76.8K 0.01% 660
2026
Q1 		$689K Sell
1,226
-1
-0.1% -$641 0.01% 593
2025
Q4 		$830K Buy
1,227
+18
+1% +$12.3K 0.01% 554
2025
Q3 		$772K Buy
1,209
+28
+2% +$17K 0.01% 555
2025
Q2 		$633K Sell
1,181
-330
-22% -$158K 0.01% 586
2025
Q1 		$635K Sell
1,511
-180
-11% -$78.2K 0.01% 568
2024
Q4 		$699K Sell
1,691
-379
-18% -$166K 0.01% 540
2024
Q3 		$1.15M Buy
2,070
+171
+9% +$83.1K 0.02% 447
2024
Q2 		$925K Buy
1,899
+11
+0.6% +$5.52K 0.01% 483
2024
Q1 		$1.02M Sell
1,888
-182
-9% -$99.5K 0.02% 476
2023
Q4 		$1.15M Sell
2,070
-18
-0.9% -$8.45K 0.02% 454
2023
Q3 		$913K Buy
2,088
+12
+0.6% +$5.98K 0.02% 473
2023
Q2 		$1.04M Buy
+2,076
New +$995K 0.02% 461

Other funds holding IDXX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Pinnacle Associates's IDXX Position: Q2 2026 in Review

Pinnacle Associates reduced its Idexx Laboratories (IDXX) stake by 11% in Q2 2026, selling an estimated $76.8K and leaving 1,089 shares worth $573K. The position accounts for 0.01% of the portfolio, ranked #660.

Pinnacle Associates first reported a position in IDXX in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.15M in Q3 2024. 1,302 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Pinnacle Associates held 1,089 shares of Idexx Laboratories worth $573K as of Q2 2026.
  • Pinnacle Associates sold 137 Idexx Laboratories shares in Q2 2026, an estimated $76.8K.
  • Idexx Laboratories made up 0.01% of Pinnacle Associates's portfolio in Q2 2026, its #660 holding.
  • Pinnacle Associates first reported a position in Idexx Laboratories in Q2 2023 and has held it in 13 quarters since.
  • Pinnacle Associates's Idexx Laboratories position peaked at $1.15M in Q3 2024.
  • 1,302 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Pinnacle Associates's 13F filing for Q2 2026, filed 3 Aug 2026.